Abstract: A display device includes a light guide plate, a cover lens, a first optical layer, a second optical layer and a display. The light guide plate has a first surface and a second surface opposite to the first surface. The cover lens is disposed on the first surface of the light guide plate. The first optical layer is disposed between the first surface and the cover lens. The second optical layer is disposed between the first surface and the first optical layer. For visible light, a light absorption rate of the first optical layer is larger than or equal to a light absorption rate of the second optical layer. The display is disposed on the second surface of the light guide plate.

Abstract: An implantable micro-biosensor a substrate, a first electrode, a second electrode, a third electrode, and a chemical reagent layer. The first electrode is disposed on the substrate and used as a counter electrode. The second electrode is disposed on the substrate and spaced apart from the first electrode. The third electrode is disposed on the substrate and used as a working electrode. The chemical reagent layer at least covers a sensing section of the third electrode so as to permit the third electrode to selectively cooperate with the first electrode or the first and second electrodes to measure a physiological signal in response to the physiological parameter of the analyte.

Abstract: An implantable micro-biosensor a substrate, a first electrode, a second electrode, a third electrode, and a chemical reagent layer. The first electrode is disposed on the substrate and used as a counter electrode. The second electrode is disposed on the substrate and spaced apart from the first electrode. The third electrode is disposed on the substrate and used as a working electrode. The chemical reagent layer at least covers a sensing section of the third electrode so as to permit the third electrode to selectively cooperate with the first electrode or the first and second electrodes to measure a physiological signal in response to the physiological parameter of the analyte.

Abstract: A reflective active device array substrate includes a substrate, a plurality of active devices, a protective layer, and a plurality of metal oxide conductor layers. The active devices are dispersedly disposed on the substrate. The protective layer is disposed on the substrate and covers the active devices. The protective layer has a plurality of openings, and each of the openings exposes a source or a drain of the corresponding active device, respectively. The metal oxide conductor layers are disposed on the substrate and cover the protective layer. Each of the metal oxide conductor layers is electrically connected to the source or the drain of the corresponding active device through the corresponding opening.

Abstract: An anti-glare layer and a manufacturing method thereof are provided. The manufacturing method of the anti-glare layer includes providing a substrate, coating an anti-glare material layer on the substrate, and performing a photolithography process on the anti-glare material layer through a gray-scale mask to form the anti-glare layer. The anti-glare layer includes multiple protrusion portions with different heights.

Abstract: A display device includes a light guide plate, a cover lens, a first optical layer, a second optical layer and a display. The light guide plate has a first surface and a second surface opposite to the first surface. The cover lens is disposed on the first surface of the light guide plate. The first optical layer is disposed between the first surface and the cover lens. The second optical layer is disposed between the first surface and the first optical layer. For visible light, a light absorption rate of the first optical layer is larger than or equal to a light absorption rate of the second optical layer. The display is disposed on the second surface of the light guide plate.

Abstract: Provided is an inspection tool for a touch panel, including a substrate adapted to be placed on the touch panel and multiple protrusions disposed on the substrate in correspondence to multiple touch inspection points and arranged along an inspection trajectory. An inspection method for a touch panel is also provided.

Abstract: A display apparatus, including a display panel and a first driver, is provided. The display panel includes multiple pixel circuits and multiple first wires. The first wires are configured to transmit multiple first driving signals. Each of the first wires includes a first portion and a second portion. The first driving signal is transmitted in the first portion and the second portion in different directions. The first driver is coupled to the display panel. The first driver is configured to output the driving signals to drive the display panel.

Abstract: A display device includes a pixel array, at least one flexible substrate, and at least one optical blocking layer. The flexible substrate is located below the pixel array. The optical blocking layer is located between the flexible substrate and the pixel array. The optical blocking layer includes a first sub-layer and a second sub-layer. The first sub-layer is located between the second sub-layer and the flexible substrate, and a refractive index of the first sub-layer is different from a refractive index of the second sub-layer.

Abstract: A display apparatus, including a display panel and a first driver, is provided. The display panel includes multiple pixel circuits and multiple first wires. The first wires are configured to transmit multiple first driving signals. Each of the first wires includes a first portion and a second portion. The first driving signal is transmitted in the first portion and the second portion in different directions. The first driver is coupled to the display panel. The first driver is configured to output the driving signals to drive the display panel.

Abstract: A touch structure including an insulating substrate, an electromagnetic shielding structure layer, a sensing circuit structure layer, a first insulating layer, and a second insulating layer is provided. The electromagnetic shielding structure layer is disposed on the insulating substrate, and located between the insulating substrate and the sensing circuit structure layer. The sensing circuit structure layer is disposed on the insulating substrate, and includes a first sensing circuit layer and a second sensing circuit layer. The first insulating layer is disposed between the electromagnetic shielding structure layer and the first sensing circuit layer. The second insulating layer is disposed between the first sensing circuit layer and the second sensing circuit layer.

Abstract: A display device includes a pixel array, at least one flexible substrate, and at least one optical blocking layer. The flexible substrate is located below the pixel array. The optical blocking layer is located between the flexible substrate and the pixel array. The optical blocking layer includes a first sub-layer and a second sub-layer. The first sub-layer is located between the second sub-layer and the flexible substrate, and a refractive index of the first sub-layer is different from a refractive index of the second sub-layer.

Abstract: The present invention relates to therapeutic ADCs comprising a drug attached to an anti-cancer antibody or antigen-binding antibody fragment. Preferably the drug is SN-38. More preferably the antibody or fragment thereof binds to Trop-2 and the therapy is used to treat a Trop-2 positive cancer. Most preferably the antibody is hRS7. The ADC is administered to a subject with a cancer in combination with an ABCG2 inhibitor. The combination therapy is effective to treat cancers that are resistant to drug alone and/or to ADC alone.

Abstract: A touch structure including an insulating substrate, an electromagnetic shielding structure layer, a sensing circuit structure layer, a first insulating layer, and a second insulating layer is provided. The electromagnetic shielding structure layer is disposed on the insulating substrate, and located between the insulating substrate and the sensing circuit structure layer. The sensing circuit structure layer is disposed on the insulating substrate, and includes a first sensing circuit layer and a second sensing circuit layer. The first insulating layer is disposed between the electromagnetic shielding structure layer and the first sensing circuit layer. The second insulating layer is disposed between the first sensing circuit layer and the second sensing circuit layer.

Abstract: A reflective active device array substrate includes a substrate, a plurality of active devices, a protective layer, and a plurality of metal oxide conductor layers. The active devices are dispersedly disposed on the substrate. The protective layer is disposed on the substrate and covers the active devices. The protective layer has a plurality of openings, and each of the openings exposes a source or a drain of the corresponding active device, respectively. The metal oxide conductor layers are disposed on the substrate and cover the protective layer. Each of the metal oxide conductor layers is electrically connected to the source or the drain of the corresponding active device through the corresponding opening.

Abstract: The present invention concerns compositions and methods of use of anti-PD-1 antibodies comprising CDR sequences corresponding to SEQ ID NO:1 to SEQ ID NO:6. Preferably the antibody is a humanized antibody comprising the variable region amino acid sequences of SEQ ID NO: 9 and SEQ ID NO:10. The antibodies are of use to treat cancer and may be administered alone or with another standard anti-cancer therapy. The methods may comprise administering the anti-PD-1 antibody or antigen-binding fragment thereof in combination with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-?), and/or other checkpoint inhibitor antibodies.

Abstract: The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for Trop-2 (EGP-1) and at least one binding site for CD3. The bispecific antibodies are of use for inducing an immune response against a Trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate. The methods may comprising administering the bispecific antibody alone, or with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-?), and/or checkpoint inhibitor antibodies. The bispecific antibody is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of Trop-2+ cancer cells. The cytotoxic immune response is enhanced by co-administration of interferon, checkpoint inhibitor antibody and/or ADC.

Abstract: Described herein are compositions and methods of use of anti-Trop-2 antibodies or antigen-binding fragment thereof to isolate, enrich, detect, diagnose and/or characterize circulating tumor cells (CTCs) from patients with a Trop-2 positive cancer. Preferably, the antibody is an RS7, 162-46.2 or MAB650 antibody. The compositions and methods are of use to detect, diagnose and/or treat metastatic Trop-2+ cancers, such as breast, ovarian, cervical, endometrial, lung, prostate, colon, rectum, stomach, esophageal, bladder, renal, pancreatic, thyroid, epithelial or head-and-neck cancer.

Abstract: Described herein are compositions and methods of use of anti-Trop-2 antibodies or antigen-binding fragment thereof to isolate, enrich, detect, diagnose and/or characterize circulating tumor cells (CTCs) from patients with a Trop-2 positive cancer. Preferably, the antibody is an RS7, 162-46.2 or MAB650 antibody. The compositions and methods are of use to detect, diagnose and/or treat metastatic Trop-2+ cancers, such as breast, ovarian, cervical, endometrial, lung, prostate, colon, rectum, stomach, esophageal, bladder, renal, pancreatic, thyroid, epithelial or head-and-neck cancer.

Abstract: The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one anti-TNF-? antibody or antigen-binding fragment thereof and at least one anti-IL-6 antibody or antigen-binding fragment thereof. Preferably, the bispecific antibody is in the form of a DNL® complex. The anti-TNF-? or anti-IL-6 antibodies may comprise specific CDR sequences disclosed herein. The compositions and methods are of use to treat autoimmune disease, immune system dysfunction or inflammatory disease, as disclosed herein.